STOCK TITAN

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Cellectis (CLLS) has released its monthly information on share capital and voting rights as of September 30, 2024. The company reported a total of 100,093,873 shares in the capital and 88,569,683 voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.

Cellectis is listed on the Euronext Growth market with the ISIN code FR0010425595. For additional information, investors and media can contact the company's designated representatives, including the Director of Communications and the Chief of Staff to the CEO. The Interim Chief Financial Officer is available for investor relations inquiries.

Cellectis (CLLS) ha pubblicato le informazioni mensili sul capitale sociale e sui diritti di voto al 30 settembre 2024. L'azienda ha riportato un totale di 100.093.873 azioni nel capitale e 88.569.683 diritti di voto. Queste informazioni sono divulgate conformemente all'Articolo 223-16 del Regolamento Generale dell'autorità di mercato finanziario francese.

Cellectis è quotata sul mercato Euronext Growth con il codice ISIN FR0010425595. Per ulteriori informazioni, investitori e media possono contattare i rappresentanti designati dell'azienda, inclusi il Direttore della Comunicazione e il Capo di Gabinetto del CEO. Il Direttore Finanziario Interinale è disponibile per le richieste relative alle relazioni con gli investitori.

Cellectis (CLLS) ha publicado su información mensual sobre el capital social y los derechos de voto al 30 de septiembre de 2024. La compañía informó un total de 100.093.873 acciones en el capital y 88.569.683 derechos de voto. Esta información es divulgada en cumplimiento del Artículo 223-16 del Reglamento General de la autoridad del mercado financiero francés.

Cellectis está listada en el mercado Euronext Growth con el código ISIN FR0010425595. Para información adicional, los inversores y los medios pueden contactar a los representantes designados de la compañía, incluyendo al Director de Comunicaciones y al Jefe de Personal del CEO. El Director Financiero Interino está disponible para consultas sobre relaciones con inversores.

Cellectis (CLLS)는 2024년 9월 30일 기준 주식 자본 및 의결권에 대한 월간 정보를 발표했습니다. 회사는 총 100,093,873주의 자본과 88,569,683개의 의결권을 보고했습니다. 이 정보는 프랑스 금융 시장 당국의 일반 규정 223-16 조에 따라 공개됩니다.

Cellectis는 ISIN 코드 FR0010425595로 Euronext Growth 시장에 상장되어 있습니다. 추가 정보에 대한 문의는 투자자와 언론이 회사의 지정된 대표자, 즉 커뮤니케이션 이사 및 CEO의 비서실장에게 연락할 수 있습니다. 재무담당 임시 이사는 투자자 관계 문의에 대해 이용 가능합니다.

Cellectis (CLLS) a publié ses informations mensuelles sur le capital social et les droits de vote au 30 septembre 2024. La société a déclaré un total de 100 093 873 actions dans le capital et 88 569 683 droits de vote. Ces informations sont divulguées conformément à l'article 223-16 du Règlement Général de l'autorité des marchés financiers française.

Cellectis est cotée sur le marché Euronext Growth avec le code ISIN FR0010425595. Pour des informations supplémentaires, les investisseurs et les médias peuvent contacter les représentants désignés de la société, y compris le Directeur de la Communication et le Chef de Cabinet du PDG. Le Directeur financier par intérim est disponible pour les demandes relatives aux relations avec les investisseurs.

Cellectis (CLLS) hat seine monatlichen Informationen zum Aktienkapital und zu den Stimmenrechten zum 30. September 2024 veröffentlicht. Das Unternehmen berichtete von insgesamt 100.093.873 Aktien im Kapital und 88.569.683 Stimmenrechten. Diese Informationen werden gemäß Artikel 223-16 der Allgemeinen Vorschriften der französischen Finanzmarktaufsicht offengelegt.

Cellectis ist an der Euronext Growth Börse mit der ISIN-Nummer FR0010425595 notiert. Für weitere Informationen können Investoren und Medien die ausgewählten Vertreter des Unternehmens, einschließlich des Kommunikationsdirektors und des Chief of Staff des CEO, kontaktieren. Der Interim Chief Financial Officer steht für Anfragen bezüglich der Investorenbeziehungen zur Verfügung.

Positive
  • None.
Negative
  • None.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Oct. 02, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting rights
09/30/2024100,093,87388,569,683


For further information on Cellectis, please contact:
     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contacts:       

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com

 

 

 

Attachment


FAQ

What is Cellectis' (CLLS) total number of shares as of September 30, 2024?

As of September 30, 2024, Cellectis (CLLS) reported a total of 100,093,873 shares in the capital.

How many voting rights does Cellectis (CLLS) have as of September 30, 2024?

Cellectis (CLLS) reported 88,569,683 voting rights as of September 30, 2024.

On which market is Cellectis (CLLS) listed?

Cellectis (CLLS) is listed on the Euronext Growth market.

What is the ISIN code for Cellectis (CLLS) stock?

The ISIN code for Cellectis (CLLS) stock is FR0010425595.

Cellectis S.A. American Depositary Shares

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Stock Data

180.17M
72.09M
3.87%
17.13%
0.36%
Biotechnology
Healthcare
Link
United States of America
Paris